Skip to content

In the BioHarmony Drug Report Database

Brexpiprazole

Rexulti, Rxulti (brexpiprazole) is a small molecule pharmaceutical. Brexpiprazole was first approved as Rexulti on 2015-07-10. It is used to treat major depressive disorder, schizophrenia, and schizophrenia spectrum and other psychotic disorders in the USA. It has been approved in Europe to treat schizophrenia. It is known to target D(2) dopamine receptor. Rexulti's patents are valid until 2032-10-12 (FDA).
Trade Name Rxulti
Common Name Brexpiprazole
Indication major depressive disorder, schizophrenia, schizophrenia spectrum and other psychotic disorders
Drug Class Antiulcer agents (benzimidazole derivatives)
Brexpiprazole
Get full access now